Optimal Management of Biologics in Crohn’s Disease

EP. 1: Overview of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 23rd 2022

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, provide insight on the pathophysiology of Crohn’s Disease (CD), associated risk factors, and diagnosis of disease.

EP. 2: Diagnosis of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 23rd 2022

Dr Anita Afzali and Dr Bincy P. Abraham review the diagnostic workup for Crohn’s disease and challenges in diagnosing the disease.

EP. 3: Goals of Therapy for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 30th 2022

Experts in gastroenterology review goals of therapy for the management of Crohn’s disease, utilizing a treat-to-target approach for treatment, and the importance of shared decision-making.

EP. 4: Approaching Treatment for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 30th 2022

Dr Bincy P. Abraham leads a discussion on factors to consider when selecting a therapy for the management of Crohn’s disease.

EP. 5: Using Biologics in Crohn’s Disease Treatment

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 7th 2022

Drs Miguel Regueiro, Jennifer Seminerio, Anita Afzali, and David Hudesman review currently available biologic therapies for moderate-to-severe Crohn’s disease and the evolution of the disease treatment landscape.

EP. 6: Treatment Selection for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 7th 2022

Drs Bincy P. Abraham, Miguel Regueiro, David P. Hudesman, Anita Afzali, and Jennifer Seminerio provide insight on approaching the optimal therapy for patients with Crohn’s disease in the frontline and second-line settings.

EP. 7: Role of IL 12/23 Inhibitors for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 14th 2022

Jennifer Seminerio, MD, and Bincy P. Abraham, MD, MS, AGAF, FACG, share their perspective on the use of IL-12/23 inhibitors in clinical practice for the management of Crohn’s disease.

EP. 8: IL-23 Inhibitors and IL-12/23 Inhibitors for Crohn’s Disease Management

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 14th 2022

Dr Miguel Regueiro comments on the safety and efficacy of approved IL-23 inhibitors and IL-12/23 inhibitors for the treatment of Crohn’s disease.

EP. 9: Durability of IL-12/23 Inhibitors in Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 21st 2022

Jennifer Seminerio, MD, discusses long-term outcomes and clinical remission rates for patients on an IL/23 inhibitor for Crohn’s disease.

EP. 10: Real-World Implications of Novel Crohn’s Disease Therapies

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 21st 2022

Anita Afzali, MD, MPH, MHCM, FACG, AGAF, explores clinical implications of newer therapies for Crohn’s disease in the real-world setting.

EP. 11: Selecting Treatment Options for Elderly Patients in Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 28th 2022

Dr Bincy P. Abraham examines age considerations and comorbidities when choosing a therapy for elderly patients with Crohn’s disease.

EP. 12: Using Selective IL-23 Inhibitors for the Treatment of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 28th 2022

Experts in gastroenterology review the use of IL-23 inhibitors such as guselkumab and risankizumab-rzaa for the management of Crohn’s disease.

EP. 13: Role of Biosimilars for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 4th 2023

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, comment on emerging data for interchangeability of biosimilars and biologics when treating Crohn’s disease.

EP. 14: Emerging Therapies and Challenges for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 4th 2023

Dr Anita Afzali and Miguel Regueiro discuss emerging therapies and combinations in the pipeline for Crohn’s disease as well as unmet needs in the field for disease management.